Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men

Julie Berg Schmidt; Nikolaj Ture Gregersen; Sue D Pedersen; Johanne L Arentoft; Christian Ritz; Thue W. Schwartz; Jens Juul Holst; Arne Astrup; Anders Mikael Sjödin

doi:10.1152/ajpendo.00569.2013

Effects of PYY_3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men

Julie Berg Schmidt, Nikolaj Ture Gregersen, Sue D Pedersen, Johanne L Arentoft, Christian Ritz, Thue W. Schwartz, Jens Juul Holst, Arne Astrup, Anders Mikael Sjödin

83 Citations (Scopus)

Abstract

Our aim was to examine the effects of GLP-1 and PYY_3-36 separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin, and vital signs in healthy overweight men. Twenty-five healthy male subjects participated in this randomized, double-blinded, placebo-controlled, four-arm crossover study (BMI 29 ± 3 kg/m², age 33 ± 9 yr). On separate days they received a 150-min intravenous infusion of 1) 0.8 pmol·kg^-1·min^-1 PYY_3-36, 2) 1.0 pmol·kg^-1·min^-1 GLP-1, 3) GLP-1 + PYY_3-3, or 4) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs, and blood variables were collected throughout the infusion period. No effect on energy intake was found after monoinfusions of PYY_3-36 (-4.2 ± 4.8%, P = 0.8) or GLP-1 (-3.0 ± 4.5%, P = 0.9). However, the coinfusion reduced energy intake compared with placebo (-30.4 ± 6.5%, P < 0.0001) and more than the sum of the monoinfusions (P < 0.001), demonstrating a synergistic effect. Coinfusion slightly increased sensation of nausea (P < 0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared with placebo (all P < 0.05); however, infusions of GLP-1 + PYY_3-36 resulted in an additional decrease compared with the monoinfusions (both P < 0.01). We conclude that coinfusion of GLP-1 and PYY_3-36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY_3-36 in combination compared with placebo. Coinfusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of these factors could explain the reduction in energy intake.

Original language	English
Journal	American Journal of Physiology: Endocrinology and Metabolism
Volume	306
Issue number	11
Pages (from-to)	E1248-E1256
Number of pages	9
ISSN	0193-1849
DOIs	https://doi.org/10.1152/ajpendo.00569.2013
Publication status	Published - 1 Jun 2014

Access to Document

10.1152/ajpendo.00569.2013

Cite this

Schmidt, J. B., Gregersen, N. T., Pedersen, S. D., Arentoft, J. L., Ritz, C., Schwartz, T. W., Holst, J. J., Astrup, A., & Sjödin, A. M. (2014). Effects of PYY_3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men. American Journal of Physiology: Endocrinology and Metabolism, 306(11), E1248-E1256. https://doi.org/10.1152/ajpendo.00569.2013

@article{bead609efd35449da819f5c6ad2e42e3,

title = "Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men",

abstract = "Our aim was to examine the effects of GLP-1 and PYY3-36 separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin, and vital signs in healthy overweight men. Twenty-five healthy male subjects participated in this randomized, double-blinded, placebo-controlled, four-arm crossover study (BMI 29 ± 3 kg/m2, age 33 ± 9 yr). On separate days they received a 150-min intravenous infusion of 1) 0.8 pmol·kg-1·min-1 PYY3-36, 2) 1.0 pmol·kg-1·min-1 GLP-1, 3) GLP-1 + PYY3-3, or 4) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs, and blood variables were collected throughout the infusion period. No effect on energy intake was found after monoinfusions of PYY3-36 (-4.2 ± 4.8%, P = 0.8) or GLP-1 (-3.0 ± 4.5%, P = 0.9). However, the coinfusion reduced energy intake compared with placebo (-30.4 ± 6.5%, P < 0.0001) and more than the sum of the monoinfusions (P < 0.001), demonstrating a synergistic effect. Coinfusion slightly increased sensation of nausea (P < 0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared with placebo (all P < 0.05); however, infusions of GLP-1 + PYY3-36 resulted in an additional decrease compared with the monoinfusions (both P < 0.01). We conclude that coinfusion of GLP-1 and PYY3-36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY3-36 in combination compared with placebo. Coinfusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of these factors could explain the reduction in energy intake.",

author = "Schmidt, {Julie Berg} and Gregersen, {Nikolaj Ture} and Pedersen, {Sue D} and Arentoft, {Johanne L} and Christian Ritz and Schwartz, {Thue W.} and Holst, {Jens Juul} and Arne Astrup and Sj{\"o}din, {Anders Mikael}",

note = "CURIS 2014 NEXS 112",

year = "2014",

month = jun,

day = "1",

doi = "10.1152/ajpendo.00569.2013",

language = "English",

volume = "306",

pages = "E1248--E1256",

journal = "American Journal of Physiology: Endocrinology and Metabolism",

issn = "0193-1849",

publisher = "American Physiological Society",

number = "11",

}

TY - JOUR

T1 - Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men

AU - Schmidt, Julie Berg

AU - Gregersen, Nikolaj Ture

AU - Pedersen, Sue D

AU - Arentoft, Johanne L

AU - Ritz, Christian

AU - Schwartz, Thue W.

AU - Holst, Jens Juul

AU - Astrup, Arne

AU - Sjödin, Anders Mikael

N1 - CURIS 2014 NEXS 112

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Our aim was to examine the effects of GLP-1 and PYY3-36 separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin, and vital signs in healthy overweight men. Twenty-five healthy male subjects participated in this randomized, double-blinded, placebo-controlled, four-arm crossover study (BMI 29 ± 3 kg/m2, age 33 ± 9 yr). On separate days they received a 150-min intravenous infusion of 1) 0.8 pmol·kg-1·min-1 PYY3-36, 2) 1.0 pmol·kg-1·min-1 GLP-1, 3) GLP-1 + PYY3-3, or 4) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs, and blood variables were collected throughout the infusion period. No effect on energy intake was found after monoinfusions of PYY3-36 (-4.2 ± 4.8%, P = 0.8) or GLP-1 (-3.0 ± 4.5%, P = 0.9). However, the coinfusion reduced energy intake compared with placebo (-30.4 ± 6.5%, P < 0.0001) and more than the sum of the monoinfusions (P < 0.001), demonstrating a synergistic effect. Coinfusion slightly increased sensation of nausea (P < 0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared with placebo (all P < 0.05); however, infusions of GLP-1 + PYY3-36 resulted in an additional decrease compared with the monoinfusions (both P < 0.01). We conclude that coinfusion of GLP-1 and PYY3-36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY3-36 in combination compared with placebo. Coinfusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of these factors could explain the reduction in energy intake.

AB - Our aim was to examine the effects of GLP-1 and PYY3-36 separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin, and vital signs in healthy overweight men. Twenty-five healthy male subjects participated in this randomized, double-blinded, placebo-controlled, four-arm crossover study (BMI 29 ± 3 kg/m2, age 33 ± 9 yr). On separate days they received a 150-min intravenous infusion of 1) 0.8 pmol·kg-1·min-1 PYY3-36, 2) 1.0 pmol·kg-1·min-1 GLP-1, 3) GLP-1 + PYY3-3, or 4) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs, and blood variables were collected throughout the infusion period. No effect on energy intake was found after monoinfusions of PYY3-36 (-4.2 ± 4.8%, P = 0.8) or GLP-1 (-3.0 ± 4.5%, P = 0.9). However, the coinfusion reduced energy intake compared with placebo (-30.4 ± 6.5%, P < 0.0001) and more than the sum of the monoinfusions (P < 0.001), demonstrating a synergistic effect. Coinfusion slightly increased sensation of nausea (P < 0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared with placebo (all P < 0.05); however, infusions of GLP-1 + PYY3-36 resulted in an additional decrease compared with the monoinfusions (both P < 0.01). We conclude that coinfusion of GLP-1 and PYY3-36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY3-36 in combination compared with placebo. Coinfusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of these factors could explain the reduction in energy intake.

U2 - 10.1152/ajpendo.00569.2013

DO - 10.1152/ajpendo.00569.2013

M3 - Journal article

C2 - 24735885

SN - 0193-1849

VL - 306

SP - E1248-E1256

JO - American Journal of Physiology: Endocrinology and Metabolism

JF - American Journal of Physiology: Endocrinology and Metabolism

IS - 11

ER -

Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men

Abstract

Access to Document

Fingerprint

Cite this

Effects of PYY_3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men